Compare Novo Nordisk A/S (NVO) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ZIM Integrated Shipping Services Ltd — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while ZIM Integrated Shipping Services Ltd trades at $25.24 (market cap $2.96B). The key difference: Novo Nordisk A/S is far larger — about 70.2× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| NVO | ZIM | |
|---|---|---|
Market Cap | $207.85B | $2.96B |
Sector | Health | Industrials |
52-Week High | $63.98 | $29.27 |
52-Week Low | $35.29 | $12.44 |
Enterprise Value | $222.55B | $6.81B |
Dividend Yield | 3.81% | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
ZIM trades at $25.27, up 0.24% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net income of $479.20 million in 2025, but profitability is expected to decline sharply in 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and pressure from lower freight rates.
The outlook is cautious, with analysts evenly split between hold and sell ratings and a consensus price target of $16.75, well below the current price. Key risks include regulatory hurdles for the merger, volatile shipping rates, and declining earnings. Upside depends on successful deal execution or improved operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
